DermTech (DMTK) Stock Price, News & Analysis

Company Overview

DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.05 to $0.42
• 52-Week Range: N/A
• Volume: 3.66 million shs
• Average Volume: 1.07 million shs
• Market Capitalization: $3.29 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.07
• Consensus Rating: Hold

DMTK Stock Analysis - Frequently Asked Questions

How were DermTech's earnings last quarter?

DermTech, Inc. (NASDAQ:DMTK) released its earnings results on Tuesday, November, 9th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.65) by $0.03. The company earned $3.03 million during the quarter, compared to the consensus estimate of $3.40 million. DermTech had a negative trailing twelve-month return on equity of 138.79% and a negative net margin of 572.19%.

What other stocks do shareholders of DermTech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that DermTech investors own include CrowdStrike (CRWD), NVIDIA (NVDA), Digital Turbine (APPS), Datadog (DDOG) and Cloudflare (NET).

Company Calendar

• Last Earnings: 11/09/2021
• Today: 3/25/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical laboratories
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:DMTK
• CIK: 1651944
• Web: www.dermtech.com
• Phone: (858) 450-4222
• Fax: N/A
• Employees: 260
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $1.07
• High Stock Price Target: $1.50
• Low Stock Price Target: $0.63
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-100,890,000.00
• Net Margins: -572.19%
• Pretax Margin: -572.19%
• Return on Equity: -138.79%
• Return on Assets: -68.96%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.53
• Quick Ratio: 3.46

Sales & Book Value

• Annual Sales: $15.66 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.67 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 34,963,000
• Free Float: 33,180,000
• Market Cap: $3.29 million
• Optionable: Optionable
• Beta: 2.48